Management Team

CAR-T Cell Therapy

Overview

Advanced, Personalised Immunotherapy for Complex Blood Cancers

CAR-T Cell Therapy (Chimeric Antigen Receptor T-cell Therapy) is a highly advanced form of immunotherapy that involves modifying a patient’s own immune cells (T-cells) to recognise and destroy cancer cells more effectively. It is typically recommended for patients with certain blood cancers that are relapsed, refractory, or nonresponsive to conventional treatments. 

At Sir H. N. Reliance Foundation Hospital, we offer a comprehensive CAR-T Cell Therapy program designed to deliver personalised, high-precision cancer care through advanced cellular engineering and controlled clinical protocols.

Request a call back

Fill in the details below and our advisor will get in touch with you in the next 24 hours

Name *
Email *
Mobile *
Enquire For *
Location *
Captcha
Enter the characters shown in the image.
The Tower

CAR-T Cell Therapy is primarily used for specific types of blood cancers, particularly when standard treatments have not been effective:

  • B-cell Acute Lymphoblastic Leukaemia (ALL)
  • High Grade and low Grade Non Hodgkin’s Lymphoma like Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma

 

The Tower

CAR-T Cell Therapy is a multi-step, highly specialised process that transforms a patient’s immune cells into powerful cancer-fighting agents:

  • Cell Collection (Leukapheresis) T-cells are collected from the patient’s blood through a specialised procedure.
  • Genetic Modification In a laboratory, T-cells are engineered with a chimeric antigen receptor (CAR) that enables them to identify cancer cells.
  • Cell Expansion These modified cells are multiplied to create millions of CAR-T cells.
  • Conditioning Therapy Patients may receive chemotherapy to prepare the body for treatment.
  • Cell Infusion The engineered CAR-T cells are infused back into the bloodstream, where they actively seek and destroy cancer cells.
  • Monitoring & Recovery Patients are closely monitored for response and potential side effects in a controlled clinical setting. 

Once infused, CAR-T cells can continue to multiply and remain active in the body, providing ongoing immune surveillance against cancer. 

Indications for CAR-T Cell Therapy

CAR-T Cell Therapy is typically considered in the following scenarios:

  • Relapsed or refractory blood cancers like acute Lymphoblastic Leukaemia (ALL) and Non Hodgkin’s Lymphoma.
The Tower
  • Advanced Cellular Therapy Program Our CAR-T Cell Therapy program is built on cutting-edge cellular and precision medicine principles, enabling personalised treatment tailored to each patient’s disease biology.
  • Specialised Infrastructure & Infection Control

    Patients undergoing CAR-T therapy require intensive monitoring and controlled environments. Our facility ensures:

    • Highly controlled, infection-safe treatment zones
    • Strict aseptic protocols and controlled patient access
  • Multidisciplinary Expert Care

    The program is led by expert haemato-oncologists and supported by a collaborative team of specialists:

    • Critical care and intensivist team
    • Neurology specialists (for therapy-related neurotoxicity management)
    • Infectious disease experts
    • Specialised oncology nursing staff
    • Clinical dieticians and rehabilitation experts

    Supported by:

    • Advanced transfusion medicine services
    • Precision molecular and genetic diagnostics
  • Comprehensive Safety & Monitoring Protocols

    CAR-T therapy requires vigilant monitoring due to potential immune-related side effects. Our protocols include:

    • Continuous clinical monitoring post-infusion
    • Early detection and management of cytokine release syndrome (CRS)
    • Neurological assessment and intervention protocols
    • Strict infection surveillance and control measures
  • Patient-Centric Experience

    Recognising the complexity of the treatment journey, we provide:

    • Personalised care pathways
    • Continuous patient and family counselling
    • Nutritional and psychological support
    • Premium care environments with close monitoring
  • Evaluation & Eligibility Comprehensive assessment to determine suitability for CAR-T therapy
  • Cell Collection Extraction of T-cells through apheresis
  • Conditioning Therapy Preparation of the body using chemotherapy
  • CAR-T Cell Infusion Reintroduction of engineered cells into the patient’s bloodstream
  • Monitoring & Recovery Close observation for response, side effects, and long-term outcomes

 

For More Information

Consult our specialists to understand eligibility, treatment pathways, and personalised CAR-T therapy options.


 

FAQs

CAR-T Cell Therapy (Chimeric Antigen Receptor T-cell Therapy) is an advanced form of immunotherapy that reprograms a patient's own immune cells to recognize and destroy cancer cells. T-cells are collected from the patient's blood, genetically modified in a laboratory to target specific proteins on cancer cells, and then infused back into the body to fight the disease.

CAR-T therapy is typically recommended for patients with certain blood cancers that have: Relapsed or refractory blood cancers like acute Lymphoblastic Leukaemia (ALL) and Non Hodgkin’s Lymphoma.

The CAR-T treatment process involves several steps:

  • Leukapheresis – T-cells are collected from the patient's blood
  • Genetic modification – T-cells are engineered in a laboratory to express chimeric antigen receptors
  • Cell expansion – Modified cells are multiplied to create millions of CAR-T cells
  • Conditioning chemotherapy – The patient receives low-dose chemotherapy to prepare the body
  • Infusion – CAR-T cells are infused back into the patient

The entire process typically takes 3–6 weeks from cell collection to infusion.

Yes, CAR-T therapy is usually administered as a single infusion. Unlike chemotherapy, which requires multiple cycles, most patients receive one dose of CAR-T cells. However, patients require close monitoring for several weeks after infusion and ongoing follow-up appointments to assess treatment response and long-term outcomes.
 

CAR-T therapy can cause significant but manageable side effects:

Cytokine Release Syndrome (CRS)

  • Fever, chills, and fatigue
  • Low blood pressure
  • Difficulty breathing
  • Usually occurs within the first 1–2 weeks

Neurological effects (ICANS)

  • Confusion or difficulty speaking
  • Headaches
  • Tremors or seizures in rare cases

Other potential side effects

  • Increased risk of infections due to lowered immunity
  • Low blood cell counts
  • Fatigue lasting weeks to months

Specialized medical teams monitor patients closely and have protocols to manage these side effects effectively.

Hospital stay varies based on individual response:

  • Minimum stay: 7–14 days for monitoring after infusion
  • Extended stay: 3–4 weeks if side effects require management
  • Outpatient monitoring: Patients typically need to remain near the treatment center for 4 weeks post-infusion

Your care team will provide specific guidance based on your treatment plan.

CAR-T therapy has demonstrated remarkable results in patients with previously untreatable cancers:

  • 50–90% of patients with certain blood cancers achieve initial remission
  • 30–40% of patients may achieve long-term remission lasting years
  • Response rates vary by cancer type, disease stage, and individual factors

Clinical outcomes continue to improve as the technology advances and patient selection criteria are refined.

CAR-T therapy is a highly specialized treatment performed under strict clinical protocols at certified treatment centers. While it carries risks—particularly CRS and neurological effects—these are well-characterized and manageable with current medical interventions.

Safety measures include:

  • Continuous monitoring during and after infusion
  • Trained specialists in CAR-T side effect management
  • Standardized treatment protocols
  • Access to intensive care if needed

Determining eligibility for CAR-T therapy requires a thorough evaluation. Schedule a consultation with a haemato-oncologist who will assess:

  • Your complete medical history
  • Current disease status and prior treatments
  • Overall health and organ function
  • Availability of approved CAR-T products for your cancer type

The care team will discuss potential benefits, risks, and alternative treatment options to help you make an informed decision.